Table 3.
Measures of Clinical Response by Serostatus After 4 Weeks Amisulpride Treatment
| Measure | NMDAR Ab Negative, n = 284 | NMDAR Ab Positive, n = 11 | Ba | p Value, NMDAR Ab Negative vs. Positive |
|---|---|---|---|---|
| PANSS Total, Baseline | 78.89 ± 19.28 | 74.21 ± 18.77 | 5.04 | .341 |
| PANSS Total, Posttreatment | 58.94 ± 18.32 | 50.45 ± 20.46 | 8.22 | .145 |
| Percentage Change in Total PANSS Scores | −38.01 ± 38.97 | −59.56 ± 26.91 | 19.55 | .098 |
| Percentage Change in CDSS Scores | −7.25 ± 24.81 | −10.54 ± 12.31 | 2.64 | .741 |
| CGI, Posttreatment | 4.41 ± 1.09 | 3.82 ± 1.25 | 0.604 | .075 |
| CGI Improvement | 3.34 ± 1.04 | 2.64 ± 0.67 | 4.27 | .044 |
| Number in Remission | 196 (69.3%) | 9 (81.8%) | 0.683 | .394 |
Values are presented as mean ± SD or n (%).
Ab, antibody; CDSS, Calgary Depression Scale for Schizophrenia; CGI, Clinical Global Impressions; NMDAR, NMDA receptor; PANSS, Positive and Negative Syndrome Scale.
a
Regression coefficient from multiple or logistic regression procedure.